Navigation Links
Celtic Pharma Provides Update on XERECEPT(R) Clinical Program
Date:12/5/2007

EMERYVILLE, Calif., Dec. 5 /PRNewswire-FirstCall/ -- Neurobiological Technologies, Inc. (Nasdaq: NTII) (NTI(R)) today announced that Celtic Pharmaceutical Holdings L.P. ("Celtic Pharma") presented interim results for XERECEPT(R) at the Annual Meeting for the Society of Neuro-Oncology.

Paul Freiman, President and Chief Executive Officer of NTI, stated, "We are pleased with our continuing involvement in the development of XERECEPT and the prospects for this drug, which is so urgently needed."

On December 4, 2007, Celtic Pharma, which acquired the rights and assets related to XERECEPT from NTI in November 2005, issued the following press release:

"New York, London and Bermuda, December 4, 2007 - Celtic Pharmaceutical Holdings L.P. ("Celtic Pharma") today reported interim study results for XERECEPT(R) (human corticotropin-releasing factor (hCRF)), which were presented at the 12th Annual Meeting of the Society for Neuro-Oncology ("SNO"), and provided an update on the XERECEPT(R) clinical development program.

"In a poster presentation at the SNO annual meeting, which took place in Dallas, Texas on November 15-18, 2007, Celtic Pharma disclosed interim results of an on-going, open-label extension trial, which is evaluating the long-term safety and efficacy of XERECEPT(R) as a new potential treatment for Peritumoral Brain Edema ("PBE"), or tumor-related brain swelling. The data presented at SNO demonstrated that 20 of the first 32 patients enrolled received XERECEPT(R) daily for at least 20 weeks. XERECEPT(R) was well- tolerated. Nine of the 20 patients discontinued dexamethasone altogether, and steroid side effects were resolved or improved in the majority of patients who received a reduced dexamethasone dose. The trial is currently enrolling eligible patients with primary or secondary (metastatic) brain tumors who have already completed one of two Phase III randomized, double-blind trials of XERECEPT(R) currently underway at 27 centers in the U.S., Canada, Australia and New Zealand.

""Side effects of high-dose corticosteroid treatment have a devastating effect on quality-of-life and potentially on life expectancy, and any option that significantly reduces the use of dexamethasone would be a major benefit to patients," said Dr. Patrick O'Connor, Head of Clinical Development at Celtic Pharma. "The interim data presented at SNO are promising and we remain optimistic about the prospects for XERECEPT(R)."

"Celtic Pharma also announced plans to initiate an imaging study, CPDS 0701, to assess more directly the effects of XERECEPT(R) on PBE. Sequential brain scans from some glioblastoma patients being treated with XERECEPT(R) suggest reduction of edema. The imaging study will aim to establish whether this observation can be substantiated over a larger patient population. The multicenter, open-label, randomized study will investigate the efficacy and safety of XERECEPT(R) for the reduction of PBE in patients with primary or metastatic brain tumors. The study is targeted to begin enrolling patients in early 2008 at investigational sites in the United States and Canada.

"Separately, Celtic Pharma announced the discontinuation of enrollment in study NTI 0302, a Phase III randomized, double-blind study comparing XERECEPT(R) to dexamethasone in first line treatment of symptoms associated with PBE in patients newly diagnosed with primary malignant glioma. The decision to discontinue enrollment for this trial was due to slower than anticipated recruitment and Celtic Pharma's conclusion that the new CPDS 0701 imaging study would be a more important contributor to the overall robustness of the XERECEPT(R) development program. No safety issues prompted this decision. The decision is unrelated to the on-going NTI 0303 Phase III study, which is now close to completing recruitment and is expected to reach final data analysis and conclusions in 2008.

"XERECEPT(R) is an investigational new drug that may present a steroid- sparing alternative to dexamethasone. Dexamethasone is the only treatment currently available for PBE, but this corticosteroid is associated with debilitating side effects, including vision problems, muscle and bone loss, irritability, impaired wound healing and opportunistic infections."

NTI sold the worldwide rights and assets related to XERECEPT to Celtic Pharma in November 2005. NTI is entitled to receive milestone payments upon the achievement of certain regulatory objectives and, if XERECEPT, is approved for commercial sale, NTI is entitled to receive profit-sharing payments on sales in the United States and royalties on sales elsewhere in the world.

About Neurobiological Technologies, Inc.

NTI is specialty biopharmaceutical company with expertise in identifying and acquiring promising drug candidates and in designing and managing late- stage clinical trials for central nervous system conditions. NTI is currently developing Viprinex(TM) (ancrod), a novel reperfusion agent that is in pivotal Phase 3 trials for the treatment of acute ischemic stroke. For more information, please visit the company's website: http://www.ntii.com.

Forward-Looking Statements:

Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements that involve risks and uncertainties, including the limited control we have over the development and commercialization of XERECEPT, as well as other risks detailed from time to time in our Annual Report of Form 10-K and other filings with the Securities and Exchange Commission. Actual results may differ materially from those projected. These forward-looking statements represent our judgment as of the date of the release. We undertake no obligation to update these forward- looking statements.


'/>"/>
SOURCE Neurobiological Technologies, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
5. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
6. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
7. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
8. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
9. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
10. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
11. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/20/2017)... COTTAGE, New York , February 20, 2017 /PRNewswire/ ... a regularized absorption of calcium and phosphorous minerals in ... role of vitamin D ingredients in maintaining a healthy ... or medicines containing vitamin D ingredients is growing in ... the advantage of consuming vitamin D ingredients for treatment ...
(Date:2/19/2017)... Fla. , Feb. 19, 2017  nThrive™, ... revenue cycle portfolio and thought leadership at the ... receiving a category leader award from KLAS. ... panel discussion focused on how market trends shape ... -  particularly a sophisticated, comprehensive Patient Access solution. ...
(Date:2/18/2017)... 17, 2017   Parker Waichman LLP, ... rights of victims injured by medical devices, comments ... call for better reporting. Congress required hospitals to ... concerns involving power morcellators and duodenoscopes prompted the ... how hospitals report injuries and deaths related to ...
Breaking Medicine Technology:
(Date:2/18/2017)... , ... February 17, 2017 ... ... for Devicemakers , Sponsored by Axendia, **FDAnews Free Webinar**, March 1, 2017 ... manufacturers looking to reduce their regulatory burden? Pay dividends in enhanced and ...
(Date:2/18/2017)... ... February 17, 2017 , ... Park Cities Pet Sitter President, ... on the Pet Life Radio network. The episode, which was posted this week, ... including: what factors led to Park Cities Pet Sitter’s being awarded the 2017 National ...
(Date:2/17/2017)... ... February 17, 2017 , ... ... pace. Enovate Medical has introduced an innovative workstation designed to reduce nursing fatigue ... the Encore Mobile EHR Workstation offers a lightweight, highly mobile, multi-functional alternative to ...
(Date:2/17/2017)... Falls Church, VA (PRWEB) , ... ... ... to Integrate FDA Device Approval and Reimbursement , **An FDAnews Webinar**, Feb. ... , What are the critical reimbursement questions manufacturers should be asking ...
(Date:2/17/2017)... , ... February 17, 2017 , ... ... the HIMSS17 Conference & Exhibition in Orlando, Fla., February 19-23. Visitors to the ... the most widely used electronic patient signatures solution in healthcare . ...
Breaking Medicine News(10 mins):